trial · primary record
Pembrolizumab
Carcinoma, Non-Small-Cell Lung
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2025-10-31 |
| Primary endpoint | Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) |
| Registry ID | NCT04165083 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:31:47.619Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04165083
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- PEMBROLIZUMAB · approval
- Pembrolizumab · compound